Discover the impact of hypereosinophilia on heart health, focusing on eosinophilic heart disease (EHD) and its mechanisms.

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

The following is a summary of “Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma ...

Using data from four biopsy sites, which is consistent with the FDA Guidance for Developing Drugs for the Treatment of EoE, the mean reduction in Peak Eosinophil Counts was 83% at 12 weeks. Plasma ...

Amali Samarasinghe, PhD, associate professor in the Department of Pediatrics at UT Health Science Center, describes herself as an aficionada of the alternative hypothesis. “I have a passion to uncover ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Leerink Partners analyst Thomas Smith reiterated a Hold rating on Allakos (ALLK – Research Report) yesterday and set a price target of ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK ...

Dupixent demonstrated an 86% reduction in peak oesophageal intraepithelial eosinophil count from baseline compared to a 21% ...

Eosinophilic gastroenteritis (EGE) is characterized by dense eosinophilic inflammation of one or several digestive tract sections. The symptoms include abdominal pain, weight loss, vomiting and ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...